54 completed, 17 unknown, 14 recruiting, 11 terminated. 30 Phase 2, 20 Phase 3, 13 Phase 4, 10 Phase 1, 6 Not applicable.
Follow Granulomatosis with Polyangiitis: new trials by email Literature Review of Granulomatosis with Polyangiitis trials Research Report on Granulomatosis with Polyangiitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Rituximab - ANCA Associated Vasculitis (AAV), Polyangiitis (GPA) | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2026-02-01 | 2026-03-05 |
| Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis Obinutuzumab - Granulomatosis With Polyangiitis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2025-12-19 | 2026-03-06 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Cyclophosphamide, Standard of Care (SOC), Prednisone - Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA) | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 36 | 2025-11-10 | 2026-01-30 |
| Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Rituximab, Tocilizumab, Tofacitinib - Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 42 | 2025-06-06 | 2026-04-03 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA Rapcabtagene autoleucel, Active Comparator, Glucocorticoids - ANCA Associated Vasculitis (AAV) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2025-03-13 | 2026-09-04 |
| Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3 18F-FDG, 18F-FDG PET/CT - Granulomatosis With Polyangiitis (Wegener's) | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 31 | 2025-01-01 | 2026-07-17 | |
| Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis Avacopan, prednisolone and rituximab, Prednisolone and rituximab - ANCA Associated Vasculitis (AAV) | Phase 4 | Recruiting | Chiba University | 160 | 2024-11-15 | 2025-05-04 |
| Iptacopan in Patients With ANCA Associated Vasculitis Iptacopan, Placebo, Rituximab - Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 84 | 2024-08-05 | 2026-10-15 |
| Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) CD19- BCMA CAR-T cells - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2024-10-15 |
| Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. AB-101, Rituximab, Cyclophosphamide - Rheumatoid Arthritis, Pemphigus Vulgaris | Phase 1 | Recruiting | IRIS Research and Development, LLC | 30 | 2024-05-15 | 2024-09-03 |
| Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) SC291 - Lupus Erythematosus, Systemic Lupus Erythematosus | Phase 1 | Active not recruiting | Sana Biotechnology | 7 | 2024-04-29 | 2025-11-25 |
| PR3-AAV Resilient Remission or PRRR Obinutuzumab, Rituximab - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Terminated | Mayo Clinic | 6 | 2023-06-30 | 2026-05-06 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Special Drug Use-results Survey for Long-term Use（Avacopan） Avacopan - Microscopic Polyangiitis (MPA), Granulomatosis With Polyangiitis (GPA) | Recruiting | Kissei Pharmaceutical Co., Ltd. | 250 | 2022-07-29 | 2025-01-17 | |
| Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Meperizumab injection, NUCALA® - Granulomatosis With Polyangiitis, Hemophagocytic Syndrome | Early Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 | 2022-06-01 | 2022-04-29 |
| Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia. Procalcitonin-variants ELISA-Assay - Sepsis, Pre-Eclampsia | Completed | University Hospital Muenster | 30 | 2022-02-01 | 2024-06-04 | |
| Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Tofacitinib, Methotrexate - Granulomatosis With Polyangiitis | Phase 4 | Unknown | Shanghai Zhongshan Hospital | 66 | 2021-07-01 | 2021-07-09 |
Showing 20 of 104. Sign in to see all of them.
Microscopic Polyangiitis (62) · Vasculitis (41) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (36) · Churg-Strauss Syndrome (25) · Polyarteritis Nodosa (16) · Takayasu Arteritis (15) · Giant Cell Arteritis (14) · Systemic Vasculitis (10) · IgA Vasculitis (9) · Arthritis, Rheumatoid (8) · Behcet Syndrome (8) · Lupus Erythematosus, Systemic (7) · Vasculitis, Central Nervous System (7) · Recurrence (6)
Skin Diseases (104) · Skin and Connective Tissue Diseases (104) · Cardiovascular Diseases (103) · Immune System Diseases (103) · Skin Diseases, Vascular (103) · Lung Diseases, Interstitial (102) · Lung Diseases (101) · Respiratory Tract Diseases (101) · Vascular Diseases (101) · Autoimmune Diseases (100) · Systemic Vasculitis (94) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (68) · Nervous System Diseases (67) · Brain Diseases (66) · Central Nervous System Diseases (66)
Rituximab (22) · Cyclophosphamide (11) · Prednisone (11) · Azathioprine (10) · Glucocorticoids (8) · Methotrexate (7) · Mycophenolic Acid (6) · Methylprednisolone (5) · Abatacept (4) · Prednisolone (4) · Blood Specimen Collection (3) · Etanercept (3) · Infliximab (3) · Plasma Exchange (3) · avacopan (3)
National Institute of Allergy and Infectious Diseases (NIAID) (12) · Assistance Publique - Hôpitaux de Paris (11) · University of Pennsylvania (11) · University of South Florida (7) · Cambridge University Hospitals NHS Foundation Trust (4) · Charite University, Berlin, Germany (2) · Chiba University (2) · Hoffmann-La Roche (2) · InflaRx GmbH (2) · Novartis Pharmaceuticals (2) · University Medical Center Groningen (2) · University of Oxford (2) · University of Sao Paulo General Hospital (2) · Alpine Immune Sciences, Inc. (1) · Anthera Pharmaceuticals (1)
United States (55) · France (20) · United Kingdom (19) · Canada (18) · Germany (12) · Czechia (8) · Netherlands (8) · Italy (7) · Japan (7) · Australia (6) · China (6) · Sweden (6) · Belgium (5) · Denmark (5) · India (4)
Peter A Merkel, MD, MPH (8) · Peter A. Merkel, MD, MPH (8) · Amanda M. Terry, MA (3) · Peter Merkel, MD, MPH (3) · David Jayne (2) · David Jayne, MD (2) · Jeffrey P Krischer, PhD (2) · John H. Stone, MD, MPH (2) · Loic Guillevin, MD, PhD (2) · Megan Clowse, MD, MPH (2) · Peter C. Grayson, MD (2) · Robert F Spiera, MD (2) · Ulrich Specks, MD (2) · Adrian Schreiber, PD Dr. med. (1)
PMID 33164993, PMID 34061144, PMID 39425055, PMID 11786196, PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16378799, PMID 16646004, PMID 16914703, PMID 17407214, PMID 17557758, PMID 19054820, PMID 19109574, PMID 19451574, PMID 20647199, PMID 21954229, PMID 22127969, PMID 22975753, PMID 23045170, PMID 23615499, PMID 23754238, PMID 23902481, PMID 24323392, PMID 25047592, PMID 25372085, PMID 25693055, PMID 25776953, PMID 26387933, PMID 26436651, PMID 26621483, PMID 27049404, PMID 27242368, PMID 27696762, PMID 27940595, PMID 28246067, PMID 28270229, PMID 28592297, PMID 29016646, PMID 29247107, PMID 29695500, PMID 29724729, PMID 30472651, PMID 30666823, PMID 31216123, PMID 32053298, PMID 32475029, PMID 32479166, PMID 33367837
U54AR057319 (7), 2009 (2), R01HL115041 (2), 2015 (1), 2018 (1), 2023 (1), 2025 (1)